These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36046816)

  • 1. Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.
    Vignot S; Dhanani A; Sainte-Marie I; de Ligniville Lajavardi L; Even G; Echemann M; Hulin N; Ménoret C; Maison P; Ratignier-Carbonneil C
    Front Pharmacol; 2022; 13():972660. PubMed ID: 36046816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.
    Dri DA; Praticò G; Gaucci E; Marianecci C; Gramaglia D
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
    Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
    Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
    [No Abstract]   [Full Text] [Related]  

  • 4. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan.
    Tshering D; Chejor P
    Explor Res Clin Soc Pharm; 2022 Sep; 7():100156. PubMed ID: 35859611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.
    Krendyukov A; Singhvi S; Green-Morrison Y; Zabransky M
    Front Oncol; 2022; 12():714516. PubMed ID: 36387084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance in pharmaceutical companies: An overview.
    Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research.
    Abbas N; Babar ZU
    J Pharm Policy Pract; 2021 Dec; 14(1):110. PubMed ID: 34952647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An example of Clinical Investigations Center reorganization during the COVID-19 pandemic French national lockdown].
    Ghrieb Z; Allaoua S; Huang J; Langner N; François F; Maréchal C; Jebali M; Lebbé C; Chellah A; Bergeron A; Kiladjian JJ; Daltro De Oliveira R; Soret-Dulphy J; Benajiba L
    Therapie; 2021; 76(4):347-358. PubMed ID: 33640116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuba's National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED).
    Aguilar-Guerra TL; Fajardo-Díaz EM; Gorry C
    MEDICC Rev; 2021; 23(3-4):9-14. PubMed ID: 34516531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications: Lessons Learned.
    Wang J; Wolka A; Bullok K; Anglin G; Radawski C; Noel R
    Ther Innov Regul Sci; 2016 Nov; 50(6):718-723. PubMed ID: 30231743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IV Studies: Some Insights, Clarifications, and Issues.
    Cesana BM; Biganzoli EM
    Curr Clin Pharmacol; 2018; 13(1):14-20. PubMed ID: 29651962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.